Nebenwirkungen · Talzenna
Talzenna 0.1 mg hard capsules Talzenna 0.25 mg hard capsules Talzenna 0.35 mg hard capsules Talzenna 0.5 mg hard capsules Talzenna 1 mg hard capsules · Abschnitt 4.8 · PDF-Seite 10
HOS-140594 · Präparat HOS-098546
In monotherapy studies (1 mg/day population), the most frequent myelosuppression-related adverse events associated with dose modifications were anaemia (33.5%), neutropenia (11.7%) and thrombocytopenia (9.9%) reported for up to approximately 30% of patients in the talazoparib 1 mg/day population and the one associated with permanent study drug discontinuation was anaemia reported in 0.6% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-18T15:15:00Z · SHA-256 ed4d297943838ad90546bb310100bb9880e0b3c9833c452b88d5862d4841e255 · Passage 948a30f0b59d7fb35d179b7b8f2f4240ecfdb11c12d52d3038b589b9d4e015b6 · Zeichen 6622–7025 im Abschnitt